- Home
- MIRM vs ENS Comparison
MIRM vs ENS Comparison
Compare MIRM & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | ENS |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | 9200 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.8B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MIRM | ENS |
|---|---|---|
| Price | $82.85 | $168.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $153.07 | ★ $249.48 |
| AVG Volume (30 Days) | ★ 732.8K | 441.1K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 0.65% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 3.09 |
| Revenue | $19,138,000.00 | ★ $216,125,000.00 |
| Revenue This Year | $33.62 | $3.70 |
| Revenue Next Year | $17.72 | $4.82 |
| P/E Ratio | ★ N/A | $57.33 |
| Revenue Growth | N/A | ★ 15.85 |
| 52 Week Low | $63.23 | $120.05 |
| 52 Week High | $130.00 | $244.30 |
Technical Indicators
Market Signals| Indicator | MIRM | ENS |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 38.14 |
| Support Level | $78.07 | $166.66 |
| Resistance Level | $88.31 | $182.19 |
| Average True Range (ATR) | 3.94 | 5.99 |
| MACD | 0.69 | -1.04 |
| Stochastic Oscillator | 46.34 | 8.10 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About ENS EnerSys
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.